Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aimmune Therapeutics Inc.

www.aimmune.com

Latest From Aimmune Therapeutics Inc.

US FDA's Shutdown Offers One Possible Winner

For most sponsors, shutdown's impact won’t be too dramatic – but for two peanut allergy companies, the stoppage had very different implications. 
Drug Review Drug Approval Standards

US FDA’s Biologics Center Faces Exciting 2019 After Quiet Year For Novel Approvals

CBER’s novel biologic approvals in 2018 were few, long, and with a low level of innovation. But the center’s work to build regulatory framework for emerging technologies is setting the stage for a different story in 2019.
Vaccines Biologics

Finance Watch: Recent Offerings Show Some Companies Were Ready For The Government Shutdown

Public Company Edition: The usual mid-January surge in public offerings hasn't happened this year, since the SEC can't process new filings, but Alnylam, Acceleron and others apparently were prepared for a lengthy shutdown. Also, ARM reports cell and gene therapy financing data.

Financing Business Strategies

Shutdown Bite Tightens At US FDA, But Gene Therapy To Get 50 More Reviewers

FDA continues to emphasize the routine and the positive, even though strains on staff and sponsors increase as shutdown grinds on. CBER's new clinical reviewers would oversee the clinical investigation, development and review of cell and gene therapies, although a timeline on the hiring is unclear.

Biologics Regenerative Medicine
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Immune Disorders
  • Alias(es)
  • Allergen Research Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Aimmune Therapeutics Inc.
  • Senior Management
  • Jayson Dallas, Pres. & CEO
    Eric Bjerkholt, CFO
    Jeffrey H Knapp, PhD, COO
    Daniel C Adelman, MD, CMO
    Mary Rozenman, PhD, SVP, Corp. Dev. & Strategy
  • Contact Info
  • Aimmune Therapeutics Inc.
    Phone: (650) 614-5220
    8000 Marina Blvd.
    Ste. 300
    Brisbane, CA 94005
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register